In MS, Ocrevus reduced inflammatory immune cells
Key Takeaway
Ocrevus reduced a group of inflammatory immune cells in people with MS, while Tysabri increased those cells in the blood.
What They Found
Researchers studied immune cells in people with MS starting ocrelizumab (Ocrevus). After treatment, a group of inflammatory immune cells became less common. These cells were more common in the blood of people with more aggressive relapsing MS. Researchers also found them in spinal fluid and around long-lasting areas of damage in donated MS tissue. In people treated with natalizumab (Tysabri), these cells became more common in the blood.
Who Should Care and Why
This study examined people with MS and tissue donated by people with MS. It focused on a group of immune cells linked to ongoing inflammation. The cells appeared more often in people with more aggressive relapsing disease. The findings may help explain how Ocrevus and Tysabri affect immune cells differently. The study did not show whether these cell changes improved symptoms or slowed disability.
Important Considerations
You cannot tell from this study whether changing these cells will slow MS. The abstract does not give the number of people studied. Researchers tracked immune cells during treatment and checked other groups of samples, but did not report a direct test of patient outcomes.
AI-generated summary — for informational purposes only, not medical advice
Categories:
Article Topics:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/16/2026
Two rare conditions can look like MS. An Italian study links certain treatments to more time without
Read More
10/15/2026
Researchers suggest adding a drug after stem cell transplant to help keep MS from returning. Learn h
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Brain : a journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.